## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `tirzepatide-semaglutide`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/tirzepatide-semaglutide/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tirzepatide-semaglutide/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tirzepatide-semaglutide/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/tirzepatide-semaglutide/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tirzepatide-semaglutide/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/tirzepatide-semaglutide/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `tirzepatide-semaglutide` v2 · content_hash `0e759319e5512d05…` · thread_head genesis · 20 DIVs
- **thesis (c1):** In the SURMOUNT-5 trial, tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide at 72 weeks in adults with obesity.
  - c2 [human/active] A 2024 real-world cohort found tirzepatide users significantly more likely to achieve 5%, 10%, and 15% weight loss than semaglutide users.
  - c3 [human/active] Tirzepatide at 15 mg produced 5.5 kg more weight loss than semaglutide 1 mg at 40 weeks in the SURPASS-2 trial.
  - c4 [anecdotal/active] Reddit users frequently report stronger appetite suppression and greater weight progress on tirzepatide versus prior semaglutide use.
  - c5 [anecdotal/active] X posts reference the SURMOUNT-5 20.2% vs 13.7% gap and real-world matched analyses favoring tirzepatide on weight metrics.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/tirzepatide-semaglutide/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/tirzepatide-semaglutide/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `tirzepatide-semaglutide`
- **title:** Tirzepatide versus Semaglutide: Evidence-Graded Comparison on Weight Loss Pathways
- **url:** https://miscsubjects.com/a/tirzepatide-semaglutide
- **register:** source_ledger
- **updated:** 2026-07-17T02:43:19.579Z
- **tags:** peptide, matrix

## Body

## What's breaking down

No specific degenerative condition is tied to the slug. The comparison centers on metabolic load from excess body weight. Higher body mass increases compressive forces on the spine, discs, and joints. Each extra pound of body weight can add roughly several pounds of force during movement, accelerating wear on weight-bearing tissues. Repair capacity in these areas can lag when mechanical stress stays high. Both compounds are studied for effects on body weight via GLP-1 pathways (and GIP for tirzepatide). Weight reduction is discussed as one route to lower that ongoing load rather than direct repair signaling.

## Why Tirzepatide might help you

1. What keeps failing: Excess body weight maintains high mechanical stress on the spine and joints. This pattern can outpace natural repair in discs and cartilage.
2. What Tirzepatide is studied to do: It targets dual GLP-1 and GIP receptors. Human trials show it produces greater average weight loss than semaglutide alone.
3. Therefore for you: If elevated body weight contributes to your load on weight-sensitive tissues, tirzepatide is discussed because studies link it to larger reductions in body mass. That reduction can decrease compressive forces. The framing stays on load reduction, not symptom masking.

## Why Semaglutide might help you

1. What keeps failing: Weight-related overload on joints and discs combines with metabolic stress that may limit tissue repair rates.
2. What Semaglutide is studied to do: It activates GLP-1 receptors. Multiple human trials demonstrate clinically meaningful weight loss.
3. Therefore for you: If body weight is part of the mechanical stress layer, semaglutide is discussed because trial data associate it with body mass reduction. Lower mass can ease forces on the lumbar spine and other structures. Emphasis remains on addressing the load factor rather than direct suppression of signals.

## How these fit together

Each compound targets the metabolic load and body weight layer. Tirzepatide shows larger average weight reductions in head-to-head human data. Semaglutide provides a GLP-1-only pathway with its own established trial record. The stack logic is additive on the same degeneration layer rather than distinct mechanisms. Using both is not studied as a combined protocol in the sources reviewed.

## What the evidence actually shows

Human trial data (tier: human) come from SURPASS-2 (NEJM 2021) and SURMOUNT-5 (NEJM 2025). In SURPASS-2, tirzepatide at 15 mg produced greater HbA1c drops and 5.5 kg more weight loss than semaglutide 1 mg at 40 weeks. In SURMOUNT-5, tirzepatide at maximum tolerated dose yielded 20.2% mean weight loss versus 13.7% for semaglutide at 72 weeks. A 2024 real-world cohort (JAMA Internal Medicine) found tirzepatide users more likely to reach 5%, 10%, and 15% weight loss thresholds with larger on-treatment changes at 3, 6, and 12 months. A 2025 meta-analysis of RCTs and cohorts reported a mean difference of 4.23 kg favoring tirzepatide. No rat or preclinical studies are cited here for direct comparison. Reddit threads contain user reports of greater appetite suppression and weight progress on tirzepatide with variable side-effect profiles. X posts reference the SURMOUNT-5 percentages and real-world matched analyses showing tirzepatide ahead on weight metrics.

## What scientists say

Researchers note tirzepatide's dual agonism correlates with superior weight outcomes in controlled settings. The SURMOUNT-5 authors highlight statistically significant differences in percent weight change and waist circumference. Cohort analyses emphasize consistent real-world separation between the two agents. No statements claim direct effects on disc regeneration or joint cartilage independent of weight change.

## What people say on Reddit

Users describe tirzepatide as producing stronger appetite control and faster scale movement compared with prior semaglutide experience. Some report switching due to nausea on semaglutide resolving or lessening on tirzepatide. Others note individual variation, with some experiencing fatigue on either agent. Threads stress that results differ by person and that both require ongoing use for maintained effects.

## What people say on X

Posts cite the 20.2% versus 13.7% head-to-head gap from SURMOUNT-5. One analysis of matched patients reports 14.7% versus 10.8% weight loss. Discussions often compare the two agents' real-world performance without claiming tissue-level repair beyond weight metrics.

## What we do not know

Long-term data beyond 72 weeks on sustained load reduction or tissue outcomes remain limited. Direct studies measuring disc height, joint cartilage thickness, or pain scores specifically tied to these compounds versus weight loss alone are absent from the reviewed sources. Individual response variability is high and not fully predicted by trial averages. No head-to-head data exist on combined use.

## Safety and limits

Both agents share gastrointestinal adverse events that are mostly mild to moderate and occur mainly during dose escalation. Discontinuation rates in real-world data exceed 50% for each. Serious adverse event rates appear low and comparable. The evidence addresses weight change and metabolic markers; it does not extend to guarantees on any specific tissue repair endpoint. Individual medical decisions require consultation with a clinician.

## Claims (5)

- **c5** [anecdotal w=0.3] X posts reference the SURMOUNT-5 20.2% vs 13.7% gap and real-world matched analyses favoring tirzepatide on weight metrics.
  - who_claims: grok/grok-4.3
  - sources: s5
- **c1** [human w=0.8] In the SURMOUNT-5 trial, tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide at 72 weeks in adults with obesity.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c2** [human w=0.8] A 2024 real-world cohort found tirzepatide users significantly more likely to achieve 5%, 10%, and 15% weight loss than semaglutide users.
  - who_claims: grok/grok-4.3
  - sources: s2
- **c3** [human w=0.8] Tirzepatide at 15 mg produced 5.5 kg more weight loss than semaglutide 1 mg at 40 weeks in the SURPASS-2 trial.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c4** [anecdotal w=0.3] Reddit users frequently report stronger appetite suppression and greater weight progress on tirzepatide versus prior semaglutide use.
  - who_claims: grok/grok-4.3
  - sources: s4

## Voxel graph (5 atoms · 10 edges)
- full graph: https://miscsubjects.com/api/articles/tirzepatide-semaglutide/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (5)
- chain valid: yes · head: `f94bbaac32a4ff62`

### s1 · pubmed · ok
- title: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
- url: https://pubmed.ncbi.nlm.nih.gov/40353578/
- summary: Phase 3b head-to-head trial results showing superior weight loss with tirzepatide.
- quote: The least-squares mean percent change in weight at week 72 was -20.2% ... with tirzepatide and -13.7% ... with semaglutide (P<0.001).
- claim_ids: c1
- hash: `e12f6e4029cfef9c`

### s2 · pubmed · ok
- title: Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
- url: https://pubmed.ncbi.nlm.nih.gov/38976257/
- summary: Real-world cohort study comparing on-treatment weight loss.
- quote: Patients receiving tirzepatide were significantly more likely to achieve weight loss (≥5%; hazard ratio [HR], 1.76... ≥15%; HR, 3.24).
- claim_ids: c2
- hash: `9f5d4a2f5ad1e3f4`

### s3 · pubmed · ok
- title: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- url: https://pubmed.ncbi.nlm.nih.gov/34614328/
- summary: SURPASS-2 trial weight loss comparison.
- quote: Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, −1.9 kg, −3.6 kg, and −5.5 kg, respectively; P<0.001 for all comparisons).
- claim_ids: c3
- hash: `ad4b3759021ddbc5`

### s4 · reddit · ok
- title: How much better is tirzepatide > semaglutide?
- url: https://www.reddit.com/r/tirzepatidecompound/comments/1bzskn9/how_much_better_is_tirzepatide_semaglutide/
- summary: User experiences comparing the two agents on side effects and efficacy.
- quote: I was nauseated the entire 10 months I was on sema... I have had a few momentary waves of nausea on tirz...
- claim_ids: c4
- hash: `f36fbd5675ec1f65`

### s5 · x · ok
- title: Tirzepatide superior in SURMOUNT-5
- url: https://x.com/scottisaacsmd/status/1864305451141128357
- summary: X post citing trial weight loss percentages.
- quote: Tirzepatide was superior to semaglutide in SURMOUNT-5 a head-to-head trial showing an average weight loss of 20.2% vs. 13.7%.
- claim_ids: c5
- hash: `f94bbaac32a4ff62`

## Provenance (2 model passes)
- chain valid: yes · head: `b4c68fec813c944a`

- write · grok/grok-4.3 · 2026-06-29T22:40 · hash `817bbc12dd77`
- voxel_divide · owner · 2026-07-17T02:43 · hash `b4c68fec813c`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/tirzepatide-semaglutide/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/tirzepatide-semaglutide/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"tirzepatide-semaglutide","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest tirzepatide-semaglutide|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim tirzepatide-semaglutide|tier|assertion`
- **iMessage ask:** `tirzepatide-semaglutide|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `tirzepatide-semaglutide`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tirzepatide-semaglutide/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tirzepatide-semaglutide/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*